Biodesix Lifts 2026 Outlook After Q1 Revenue Jumps 42%

Overview

• Biodesix reported Q1 revenue of $25.6 million, up 42% year over year, and raised full-year guidance to $108 million to $114 million.
• Diagnostic testing revenue rose 37% on a 29% increase in test volumes, with primary care now accounting for 15% of test orders and better pricing lifting sales.
• Development services nearly doubled, rising 99%, which executives said included a pull-forward that should even out as the year progresses.
• Gross margin improved to 84% on scale, pricing, and lab efficiencies, and the GAAP net loss narrowed to $7.8 million with a 35% improvement in adjusted EBITDA loss.
• Cash ended at $25.6 million helped by $16.8 million raised in the market, and the company plans to add about six sales reps per quarter and invest in R&D.